Nicolaus Radford, who founded Nauticus Robotics and took it all the way to IPO, shares details of his new company, PersonaAI. Image via LinkedIn

For his next act, Houston entrepreneur Nicolaus Radford has started — in what he describes as an "anti-stealth" capacity — a new company that hopes to bring humanoid robotics out of science fiction novels and into manufacturing floors.

Radford, who saw his last company, Nauticus Robotics, from founding to IPO, left the company in January. He tells InnovationMap that he started receiving some compelling offers at other robotics companies, but none of them felt like a fit. However, he just couldn't get the idea of advancing humanoid robotics out of his head.

"Humanoids are the holy grail of all of robotics," Radford says. "It's what every science fiction writer's always dreamed about.

"It is the future," he continues. "And now with this generative AI moment of 2022 where these machines look a lot more capable, flexible, reprogrammable — they can reason in real time. That's a huge deal."

Radford says he got a call from his friend, Jerry Pratt, who was the CTO at humanoid robotics company Figure AI. Pratt and Radford both worked in robotics at NASA and each have decades of experience in the tech world. The conversation really sealed the deal for Radford, and the two officially launched Persona AI in a LinkedIn post that Radford says shocked him with how much interest the community had.

Radford says that with all this interest, he wants to open up the company to more co-founders than just himself and Pratt, who's based in Florida.

"We're going to give a significant amount of the company out to the early joiners, more so than is probably typical," Radford says. "And it's because we know it takes a village, and we want to highlight that to everybody."

"We're trying to crowdsource the company," he continues. "We've coined that we're anti stealth."

Specifically, Radford says he's looking at growing the team to about 25 people in the next year, alongside raising early funding. He's looking for people with a diverse tech background with well-rounded experience.

"Robotics and humanoids in particular are just so multidisciplinary," Radford says. "Humanoids are a hundred-thousand-piece puzzle, and you're trying to put this puzzle together."

And for Radford, assembling that puzzle in Houston is of utmost importance. The company is headquartered here, and Radford is currently working with The Ion to set up an office there.

"We're exceptionally excited to put (the company) in Houston," he says. "It would be incredible for the city — there's a lot of industrial manufacturing here and a lot of warehousing. ... I still have this desire to shine a light on Houston's tech scene because I believe it is unsung, underappreciated, and quite capable."

The potential for this technology is huge — Radford estimates it as a $3 trillion market — but the first industry he plans on tackling is automotive, but he also sees promise in the medical, energy, and home industries.

"We think automotive is going to be a first-mover market. There's a lot of publicly announced partnerships between advanced robotics companies and humanoid companies and automotive," he says. "These folks are showing a willingness to put something out in the press that says they're developing a humanoid or piloting a humanoid. That's huge.

With this expressed interest, technology advancement, and large labor shortage, Radford is convinced now is the time for humanoid robotics — and for Persona AI.

"We're at a technology tipping point where it makes sense that these machines can do this, and there's an investment community willing to finance it," Radford says. "I think the first time in all of robotic history we're closer than we've ever been to making this a reality."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.